John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax. John Seymour, MBBS, FRACP, PhD, director of hematology at the Peter MacCallum Cancer Center and ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

they shed light on the selectivity of BRAF inhibitors by delineating the main structural changes occurring during dimerization and inhibitor action. Notably, they identify the two pivotal elements in ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Botox has long been touted as the “secret of youth.” However, everyone knows that it changes facial features (and not always ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...